1
|
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. Cancer Chemother Pharmacol 2019; 83:743-753. [DOI: 10.1007/s00280-018-03765-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 12/27/2018] [Indexed: 11/25/2022]
|
2
|
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Paux G, Dubois F, Xuereb L, Robert R, Andre F. Abstract P1-09-11: A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-09-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
FGFR1 amplification could mediate resistance to endocrine therapy and FGFR1 inhibition reverses this resistance. This phase Ib seeks to evaluate whether the combination of lucitanib, a potent FGFR/VEGFR/PDFGR inhibitor, in combination with fulvestrant, an endocrine agent, reverses resistance to fulvestrant.
Eligible patients for this study were postmenopausal with ER+/HER2- mBC and have relapsed during or after treatment with fulvestrant. There were 2 parts in the study: a dose allocation to assess the tolerability of the combination in terms of DLTs and MTD using a modified Continual Reassessment Method (mCRM) [part I] and a dose expansion, with patients assigned to 2 different cohorts based on FGFR amplification, to further evaluate the tolerability of the combination and to identify the recommended phase II dose (RP2D) [part II]. Surrogate target hitting biomarkers were also dosed at baseline and on-treatment. The sponsor decided to halt the clinical development in mBC indication and the study was prematurely terminated after 18 patients (15 in part I and 3 in part II). The presentation will focus on these 18 patients.
Patients had ECOG PS 0 or 1 and median number of previous treatments in metastatic setting was 3. Two doses of lucitanib (10mg daily n=9 and 12.5mg daily n=6) in combination with 500 mg/month of fulvestrant were tested in part I. At the 10mg dose level, one patient experienced a DLT (grade 3 hypertension). Based on global lucitanib development program data, it was decided to start Part II with lucitanib 10mg daily. The most common related grade ≥3 toxicities occurring in more than 10% of patients were hypertension (78%) and asthenia (22%). All patients required at least one dose interruption mainly for toxicities, while 13 patients (72%) required at least a dose reduction for toxicities. Thirteen patients (72%) withdrew from the study for disease progression, 3 (17%) for adverse events (at 10mg) and 2 (11%) for non-medical reasons. Three patients achieved a confirmed partial response (as per RECIST v1.1), one at 10mg and two at 12.5mg. About 55% of the patients experienced clinical benefit with a median duration of the benefit of 39.6 weeks and a maximun duration of the benefit of 79.1 weeks for 1 patient (PR at Cycle 4). Biomarker modulations were consistent with lucitanib mode of action; targeting VEGFRs (significant increase of VEGFA, IL8, PlGF) and FGFR1 (significant increase of FGF23).
The combination is feasible but requires close patient monitoring and intensive management of adverse events. Those are in line with the anti-angiogenic activity of lucitanib.
10mg (N=12)12.5mg (N=6)All (N=18)Objective Response Rate (ORR)n(%) 11 (8.3)2 (33.3)3 (16.7) 95% CI 3[1.5;35.4][9.7;70.0][5.8;39.2]Clinical Benefit Rate (CBR)n(%) 24 (33.3)6 (100.0)10 (55.6) 95% CI 3[13.8;61.0][61.0;100.0][33.7;75.4]Duration of Clinical Benefitmedian (weeks)28.171.339.6 95% CI 3[27.9; 32.7][29.1; 79.1][27.9; 79.1]1: CR or PR 2: CR or PR or stabilization (SD or NonCR/NonPD) >24 weeks or at end of cycle 6 3: 95% Wilson method of Confidence interval of the estimate
Citation Format: Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat M-J, Poirot C, Paux G, Dubois F, Xuereb L, Robert R, Andre F. A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-09-11.
Collapse
Affiliation(s)
- M Campone
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - T Bachelot
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - F Penault-Llorca
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - A Pallis
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - V Agrapart
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - M-J Pierrat
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - C Poirot
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - G Paux
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - F Dubois
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - L Xuereb
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - R Robert
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| | - F Andre
- Institut de Cancérologie de l'Ouest – Centre René Gauducheau, Saint-Herblain, France; Centre Léon Bérard Centre de Lutte Contre le Cancer (CLCC) de Lyon, Lyon, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut de Recherches Internationales Servier, Suresnes, France; Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
3
|
Cao J, Li J, Ji D, Shen W, Jiang L, Ma X, Pang J, Kanehisa A, Legrand F, Pallis A, Paux G, Robert R, Chen X, Letecheur P, Qiang L, Ding J. 126O A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv521.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer 2012; 106:1917-25. [PMID: 22669159 PMCID: PMC3388568 DOI: 10.1038/bjc.2012.202] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment in patients with metastatic breast cancer (MBC). METHODS The presence of CTCs was detected in 298 patients with MBC using a real-time PCR (RT-PCR assay. In 44 patients, the detection of CTCs was evaluated by both the CellSearch and the RT-PCR assay. Interaction with known prognostic factors and association of CTCs with clinical outcome were investigated. RESULTS There was a strong correlation between the detection of CTCs by both assays. CK-19mRNA-positive CTCs were detected in 201 (67%) patients and their detection was independent of various patients' clinico-pathological characteristics. The median progression-free survival (PFS; 9.2 vs 11.9 months (mo), P=0.003) and the overall survival (OS; 29.7 vs 38.9 mo, P=0.016) were significantly shorter in patients with detectable CK-19mRNA-positive CTCs compared with patients without detectable CTCs. Multivariate analysis demonstrated that oestrogen receptor status, performance status and detection of CTCs were emerged as independent prognostic factors associated with decreased PFS and OS. CONCLUSION The detection of CK-19mRNA-positive CTCs in patients with MBC before front-line therapy could define a subgroup of patients with dismal clinical outcome.
Collapse
Affiliation(s)
- N Androulakis
- Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Pallis A, Briasoulis E, Linardou H, Papadimitriou C, Bafaloukos D, Kosmidis P, Murray S. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011; 18:1613-28. [PMID: 21428885 DOI: 10.2174/092986711795471383] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Accepted: 03/16/2011] [Indexed: 11/22/2022]
Abstract
Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors (TKIs) of the EGFR tyrosine kinase. There are, however, patients with EGFR mutated tumors who do not demonstrate tumor response. The most widely accepted mechanism of 'de novo' (inherent) resistance to these TKIs involves mutations of the KRAS gene. KRAS is a downstream mediator of EGFR-induced cell signaling, such mutations appear to be mutually exclusive from EGFR mutations in lung cancer. The first molecular modifier of resistance identified in patients who developed resistance (termed 'acquired resistance') to TK inhibition was a new acquired somatic EGFR mutation (T790M). Today there is an ever-growing series of molecular events that have recently come to the forefront to explain other instances of TKI resistance not attributable to T790M or KRAS. These include a number of molecules that interact with EGFR or form part of its downstream signaling pathway such as HER-2, IGFR-1, MET and B-RAF. Considering that the majority of studies carried out to date with respect to the identification of resistant clones have not used highly sensitive techniques (e.g. allelic discrimination to identify somatic mutations), coupled with the relatively low number of studies examining multiple molecular markers and the accepted molecular heterogeneity of NSCLC raise question as to the existence of 'acquired' versus 'de-novo' resistance. By examining the current knowledge base with respect to mechanisms of resistance to EGFR TKIs in NSCLC, we explore whether 'acquired' resistance is 'de-novo' resistance in disguise, and discuss the promises and limitations of molecular stratification with respect to strategies incorporating TKIs in the treatment of NSCLC.
Collapse
Affiliation(s)
- A Pallis
- Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
| | | | | | | | | | | | | |
Collapse
|
6
|
Gioulbasanis I, Kalykaki A, Vamvakas L, Pallis A, Vardakis N, Saloustros E, Karampeazis A, Sfakiotaki G, Kalbakis K, Mavroudis D. Evaluation of mini nutritional assessment (MNA) in metastatic lung cancer patients: Correlation of laboratory values indicating malnutrition, inflammation, and cachexia with clinical data. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Vamvakas L, Karampeazis A, Agelaki S, Agelidou A, Kotsakis A, Kakolyris S, Polyzos A, Pallis A, Saloustros E, Georgoulias V. P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol 2007. [DOI: 10.1016/s1040-8428(13)70213-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
8
|
Maniadakis N, Pallis A, Fragoulakis V, Prezerakos P, Georgoulias V. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin 2007; 23:2251-7. [PMID: 17706002 DOI: 10.1185/030079907x223765] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION An economic evaluation of the irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) combination versus the irinotecan, oxaliplatin, leucovorin, 5-fluorouracil (FOLFOXIRI) regimen in patients with metastatic colorectal cancer was performed in the context of a randomised phase III study. METHODS The trial did not find any differences in efficacy and, therefore, a cost-minimisation analysis was undertaken. Treatment cost accounts for the administration of first and second line chemotherapy, for concomitant medications, for laboratory and other examinations and hospitalisations due to treatment side effects. Unit prices used reflect 2006 and are common among NHS hospitals in Greece. RESULTS The mean total cost of therapy in the FOLFOXIRI group (18,344 euros, 95% CI: 16,951 euros-19,776 euros), was significantly higher than the FOLFIRI group (12,201 euros, 95% CI: 11,011 euros-13,427 euros). Mean chemotherapy cost of the FOLFOXIRI group (9016 euros; 95% CI: 8338 euros-9669 euros) was significantly higher than that of the FOLFIRI group (4830 euros; 95% CI: 4435 euros-5231 euros). The next largest component of cost involves second line drugs, where the average cost per patient was 3306 euros (95% CI: 2479 euros-4237 euros) in the FOLFIRI group and 3996 euros (95% CI: 3196 euros-4892 euros) in the FOLFOXIRI group. The cost of hospitalisations was 1814 euros (95% CI: 1672 euros-1954 euros) in the first group and 2663 euros (95% CI: 2469 euros-2859 euros) in the second. The rest of the components represent a small part of the total cost and there are no differences in the two groups. CONCLUSION The combination of irinotecan, leucovorin, 5-fluorouracil has the same effectiveness as the combination of irinotecan, oxaliplatin, leucovorin, 5-fluorouracil in patients with metastatic colorectal cancer, nonetheless it is associated with a much lower overall treatment cost and it should be the preferred treatment regimen in this context.
Collapse
Affiliation(s)
- N Maniadakis
- University General Hospital of Heraklion, Voutes 711 10, Crete, Greece.
| | | | | | | | | |
Collapse
|
9
|
Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007; 58:275-81. [PMID: 17688969 DOI: 10.1016/j.lungcan.2007.06.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2007] [Revised: 06/07/2007] [Accepted: 06/11/2007] [Indexed: 11/19/2022]
Abstract
OBJECTIVES The combination of docetaxel/gemcitabine is an acceptable chemotherapy regimen for the treatment of non-small cell lung cancer. An economic evaluation is undertaken alongside a multi-centre randomized phase III trial, which compares docetaxel/gemcitabine combination with docetaxel monotherapy, in untreated patients with advanced/metastatic non-small cell lung cancer. METHODS Trial resource utilisation data are combined with unit price data used to evaluate the cost of chemotherapy, concomitant medications, hospitalisations, diagnostic and laboratory tests and second-line chemotherapy. Treatment cost is combined with survival to estimate the incremental cost per-life-year-saved with the combination therapy versus monotherapy. To deal with uncertainty, stochastic analysis is used to plot cost-effectiveness acceptability curves. RESULTS Median survival is 9.1 months (range 1-36.2) and 8.3 months (range 1-26.8) (p: 0.025) in the combination and monotherapy groups, respectively. The mean total treatment cost of patients with docetaxel is estimated at Euro5736 and with docetaxel/gemcitabine at Euro7417, a difference of Euro1542 (95%CI: Euro499-2561). The incremental cost per-life-year-saved of the combination therapy is euro9538 and the probability to be cost-effective is 91% at a threshold of Euro20,000, 97% at a threshold of Euro35,000 and 98% at a threshold of Euro50,000. CONCLUSIONS The data support that docetaxel/gemcitabine combination represents a cost-effective treatment option in relation to docetaxel monotherapy for patients with non-small cell lung cancer in the Greek NHS setting.
Collapse
Affiliation(s)
- N Maniadakis
- Department of Medical Oncology, University General Hospital of Heraklion, Voutes 71110, Crete, Greece.
| | | | | | | | | |
Collapse
|
10
|
Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D, Georgoulias V. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the period of adjuvant tamoxifen treatment in patients with early breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10534 Background: To evaluate the effect of adjuvant treatment with tamoxifen on the CK-19 mRNA+ circulating tumor cells (CTCs) in patients with early-stage breast cancer. Methods: CTCs were prospectively and longitudinally detected using a specific real-time PCR for CK-19 mRNA in 119 patients with estrogen and/or progesterone receptor-positive tumors during the period of tamoxifen administration. Results: Twenty-two (18.5%) patients had detectable CK-19 mRNA+ CTCs after the completion of adjuvant chemotherapy and in 15 (68.2%) of them adjuvant tamoxifen could not eliminate these cells (persistently positive). In 68 (57.1%) patients no CK-19 mRNA+ CTCs could be detected throughout the follow up period (persistently negative). Seven (46.7%) of the 15 persistently positive and six (8.8%) of the 68 persistently negative patients developed disease recurrence (p=0.00026). Persistence of CK-19 mRNA+ CTCs was associated with a significantly shorter median disease-free interval (p=0.0001) and overall survival (0.0005). Multivariate analysis revealed that the detection of CK-19 mRNA+ CTCs during the administration of tamoxifen was associated with an increased risk of relapse (HR=22.318, p=0.00006) and death (HR=13.954, p< 0.00001). Conclusions: The detection of CK-19 mRNA+ CTCs throughout the period of adjuvant tamoxifen treatment is an independent poor prognostic factor in patients with early breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Xenidis
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - V. Markos
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - S. Apostolaki
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - M. Perraki
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - A. Pallis
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - G. Sfakiotaki
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - M. Kafousi
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - E. Stathopoulos
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - S. Kakolyris
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - D. Mavroudis
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - V. Georgoulias
- School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| |
Collapse
|
11
|
Pallis A, Voutsina A, Kalikaki A, Koutsopoulos A, Souglakos J, Christophylakis C, Kentepozidis N, Giassas S, Mavroudis D, Georgoulias V. Correlation of gefitinib efficacy and detection of new EGFR mutation variants in pre-treated patients (pts) with advanced non- small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18062 Background: The efficacy of tyrosine kinase inhibitors (TKIs) of EGFR is associated with well characterized mutations on the exons 18, 19 and 21 of EGFR gene. Less common mutations could be detected in these exons but their relationship with the clinical efficacy of TKIs has not been established yet. Methods: Genomic DNA was extracted from microdissected formalin-fixed paraffin-embeded tumor tissue from 86 pts enrolled in a gefitinib expanded access program. Exons 18, 19 and 21 were amplified and subjected to direct sequencing. Results: Classical EGFR mutations (CM) were detected in 9 (10.4%) pts and other mutations variants (MV) in 19 (22%) pts. Eight (42.1%) MV were observed in exon 18, 3 (15.8%) in exon 19 and 8 (42.1%) in exon 21. Tumor Growth Control (TGC) was achieved in 88.9% (3PR and 5SD) pts with CM, 63% (2PR and 10SD) pts with MV and in 45.9% (3PR and 25SD) pts with wild type EGFR gene (WT). There was no clear association between the presence of EGFR MV and the sex, histology or smoking history. The median TTP was 64 weeks (range:4- 80+), 20 weeks (range:6–140) and 16 weeks (range:4–176+) in pts with CM, MV and WT, respectively. Nine (47.3%) pts with EGFR MV had a TTP >24 weeks. The median survival was 78 weeks (range:5–94+), 70 weeks (range:10–142) and 36 weeks (range:4–176+) in pts with CM, MV and WT, respectively. Three patients bearing mutations in exons 18, 19, and 21 progressed despite gefitinib treatment suggesting that these mutations could be related to resistance to gefitinib. Conclusions: EGFR mutation variants could be associated with response or resistance to TKIs but their low incidence requires their evaluation in a largest cohort of patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Pallis
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - A. Voutsina
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - A. Kalikaki
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - A. Koutsopoulos
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - J. Souglakos
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - C. Christophylakis
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - N. Kentepozidis
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - S. Giassas
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - D. Mavroudis
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| | - V. Georgoulias
- University General Hospital of Herakion, Heraklion, Greece; School of Medicine, University of Greece, Heraklion, Greece; University General Hospital of Heraklion, Heraklion, Greece; University Gen Hosp of Heraklion, Dpt of Med Oncol, Heraklion, Greece; IASO General Hospital, Athens, Greece; 251 Air Forces General Hospital, Athens, Greece
| |
Collapse
|
12
|
Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D, Georgoulias V. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 18:1623-31. [PMID: 17515404 DOI: 10.1093/annonc/mdm208] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the effect of adjuvant treatment with tamoxifen on the CK-19 mRNA+ cells in patients with early-stage breast cancer. PATIENTS AND METHODS CK-19 mRNA+ cells were prospectively and longitudinally detected using a specific real-time PCR assay for CK-19 mRNA in 119 patients with estrogen and/or progesterone receptor-positive tumors during the period of tamoxifen administration. RESULTS Twenty-two (18.5%) patients had detectable CK-19 mRNA+ cells after the completion of adjuvant chemotherapy and in 15 (68.2%) of them adjuvant tamoxifen could not eliminate these cells (persistently positive). In 68 (57.1%) patients, no CK-19 mRNA+ cells could be detected throughout the follow-up period (persistently negative). Seven (46.7%) of the 15 persistently positive and six (8.8%) of the 68 persistently negative patients developed disease recurrence (P = 0.00026). Persistency of CK-19 mRNA+ cells was associated with a significantly lower median disease-free interval (P = 0.0001) and overall survival (P = 0.0005). Multivariate analysis revealed that the detection of CK-19 mRNA+ cells during the administration of tamoxifen was associated with an increased risk of relapse [hazard ratio (HR) = 22.318, P = 0.00006] and death (HR = 13.954, P < 0.00001). CONCLUSIONS The detection of CK-19 mRNA+ cells throughout the period of adjuvant tamoxifen treatment is an independent poor prognostic factor in patients with early breast cancer.
Collapse
Affiliation(s)
- N Xenidis
- Department of Medical Oncology,University General Hospital of Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18:851-8. [PMID: 17301075 DOI: 10.1093/annonc/mdl502] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the prognostic value of circulating tumor cells (CTCs) expressing HER2 messenger RNA (mRNA) after the administration of adjuvant chemotherapy in women with operable breast cancer. PATIENTS AND METHODS HER2 mRNA-positive CTCs were detected by nested RT-PCR in the peripheral blood of 214 patients with stage I and II breast cancer after the completion of adjuvant chemotherapy. RESULTS HER2 mRNA-positive CTCs were detected in 45 (21%) patients. Adjuvant chemotherapy could eliminate HER2 mRNA-positive CTCs in 16 (30.2%) prechemotherapy-positive patients. Moreover, HER2 mRNA-positive CTCs were detected in eight (5%) of 161 prechemotherapy-negative patients. The detection of HER2 mRNA-positive CTCs after chemotherapy was associated with reduced disease-free interval (DFI) (P = 0.006) but not with overall survival (P = 0.2); this effect was mainly observed in node-negative patients (P = 0.04) and to a lesser extent in node-positive (P = 0.06). Multivariate analysis revealed that the detection of HER2 mRNA-positive CTCs was an independent predictive factor for DFI (hazard ratio 3.238, P < 0.0005). CONCLUSIONS The detection of HER2 mRNA-positive CTCs after the completion of adjuvant chemotherapy may provide clinically useful information concerning the efficacy of treatment and the prognosis of patients with operable breast cancer.
Collapse
Affiliation(s)
- S Apostolaki
- Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kourousis C, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. Dig Dis 2007; 25:100-5. [PMID: 17384515 DOI: 10.1159/000099177] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer. PATIENTS AND METHODS 33 patients relapsing after oxaliplatin (L-OHP)-based first-line chemotherapy were enrolled. Their median age was 69 years, 20 (61%) patients were male, and performance status (WHO) was 0, 1, and 2 in 15, 16 and 2 patients respectively; prior surgery 20 (61%) patients; adjuvant chemotherapy 11 (33%) patients, and adjuvant radiotherapy 6 (18%) patients. The number of metastatic sites was 1, 2, and > or =3 in 11, 11, and 11 patients, respectively. CPT-11 was administered on day 1 at the dose of 80 mg/m(2) in 30-90 min infusion and LV (500 mg/m(2)) on the same day as a 2-hour infusion followed by 5-FU (2,600 mg/m(2)/day) as a 22-hour infusion on day 1 for 6 subsequent weeks. The regimen was repeated every 7 weeks. RESULTS All patients were evaluable for toxicity and for response. Complete response was achieved in 2 patients (6%) and partial response in 4 patients (12%) (RR 18%, CI 5.95-35.43%); 13 patients (40%) had stable disease, and 14 (42%) progressive disease. After a median follow-up period of 9 months, the median duration of response was 5 months, the median time to progression 7.5 months, and OS 14 months. Grade 3-4 neutropenia occurred in 13 patients (39%), febrile neutropenia in 3 (9%), grade 2 anemia in 11 (33%), grade 4 thrombocytopenia in 1 (3%). Grade 3-4 diarrhea occurred in 12 patients (36%), grade 3-4 neurotoxicity in 3 (9%), and grade 3 asthenia in 4 (12%). No treatment-related deaths occurred. The median dose intensity was 85% for CPT-11, and 88% for 5-FU and LV. CONCLUSIONS The combination of weekly CPT-11 and infusional 5-FU/LV is an active and relatively well-tolerated regimen as salvage treatment in MCC.
Collapse
Affiliation(s)
- J Souglakos
- Department of Medical Oncology, University General Hospital of Heraklion, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Androulakis N, Boukovinas I, Bozionelou V, Kalykaki A, Potamianou A, Pallis A, Vamvakas L, Gkioulbasanis I, Souglakos I, Sfakiotaki G. Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14574 Background: The GC combination has become a standard of care for advanced TCC. D has demonstrated broad single agent activity in many solid tumors including bladder cancer. We evaluated the safety and the activity of their sequential administration in patients (pts) with locally advanced or metastatic TCC who have not received prior chemotherapy. Methods: Chemotherapy-naïve pts with histologically proven locally advanced or metastatic TCC were enrolled. G 1100 mg/m2 was administered over 30-minutes IV on days 1 and 15, C 80 mg/m2 on day 1 with the adequate hydration and D 80 mg/m2 over 1 h on day 15. Results: From 4/2004–12/2005, 26 pts (25 male, 1 female), median age 65.5 years (range, 48–75), (PS 0/1/2: 16/8/2) were enrolled onto the study. The majority (19pts, 73.1%) had metastatic disease. A median of 4 cycles (range 1–9) was given for a total of 113 cycles. There were 12 delayed cycles due to toxicity and 15 dose reductions. Three (16.7%) complete responses (CRs) and 6 (33.3%) partial responses (PRs) [2 of them were converted to CR with additional surgery] were observed in 18 evaluable pts [overall RR of 50%; 95% CI 26.9%-3.1%]. The median time to progression was 7.9, and the months while median survival has not yet reached. The 1-year survival is 68.86%. Gr III-IV hematologic toxicity included neutropenia (61.5%), febrile neutropenia (11.5%), anemia (7.7%) and thrombocytopenia (7.6%). Non hematologic toxicity was mild (grade III vomiting and diarrhea in 7.7% and 3.8% of the pts, respectively). There was no neutropenic sepsis or toxic death. Conclusions: The sequential administration of cisplatin, gemcitabine and docetaxel is an active treatment for pts with advanced TCC. Toxicity is not manageable and this regimen warrants further investigation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Androulakis
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - I. Boukovinas
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - V. Bozionelou
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - A. Kalykaki
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - A. Potamianou
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - A. Pallis
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - L. Vamvakas
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | | | - I. Souglakos
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| | - G. Sfakiotaki
- Hellenic Oncology Cooperative Group (HORG), Heraklion, Greece
| |
Collapse
|
16
|
Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69:384-90. [PMID: 16319509 DOI: 10.1159/000089992] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2004] [Accepted: 06/24/2004] [Indexed: 12/15/2022]
Abstract
PURPOSE To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC). METHODS Thirty consecutive, previously untreated patients with metastatic colorectal cancer, aged (median 76 years; range 70-84) were enrolled. The performance status (WHO) was 0 in 8, 1 in 16 and 2 in 6 patients; 19 (63%) patients had prior surgery and 8 (27%) adjuvant chemotherapy. CPT-11 (180 mg/m(2) as a 90 min i.v. infusion) was administered on day 1, LV (200 mg/m(2) as a 2-hour i.v. infusion), 5-FU (400 mg/m(2)/d i.v. bolus followed by 600 mg/m(2)/d as a 22-hour i.v. continuous infusion) were given on days 1 and 2 every 2 weeks. RESULTS Complete response was achieved in one (3.3%) patient and partial response in 10 (33.3%) (overall response rate: 36.6%; 95% C.I.: 26.6-48.4%); 11 (36.6%) patients had stable disease and, 8 (26.6%) disease progression. The median duration of response was 7.5 months and the median time to disease progression 7.0 months. After a median follow-up period of 17 months, the median overall survival was 14.5 months. Main toxicities were: grade 3-4 neutropenia (n = 6; 20%), grade 3 thrombocytopenia (n = 1; 3.3%), grade 2 anemia (n = 9; 30%), grade 3-4 diarrhea (n = 5; 17%) and grade 3 asthenia (n = 3; 10%). There was one treatment-related death due to neutropenic sepsis. CONCLUSIONS The FOLFIRI combination is an active regimen with manageable toxicity as front-line treatment in patients above 70 years of age.
Collapse
Affiliation(s)
- J Souglakos
- Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Mavroudis D, Perraki M, Kallergi G, Pallis A, Kanellou P, Kalmanti L, Xenidis N, Bozionelou V, Manousakis E, Georgoulias V. Molecular detection of HER2 mRNA-positive cells in the peripheral blood of patients with operable breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.668] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Mavroudis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - M. Perraki
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - G. Kallergi
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - A. Pallis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - P. Kanellou
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - L. Kalmanti
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - N. Xenidis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - V. Bozionelou
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - E. Manousakis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - V. Georgoulias
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| |
Collapse
|
18
|
Xenidis N, Mavroudis D, Kouroussis CH, Kalmanti L, Pallis A, Kanellou P, Sfakiotaki G, Perraki M, Apostolaki S, Kalykaki A, Georgoulias V. Effect of adjuvant tamoxifen and letrozol on the fate of peripheral blood CK-19 mRNA+ cells in patients with early breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.754] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Xenidis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - D. Mavroudis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | | | - L. Kalmanti
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - A. Pallis
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - P. Kanellou
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - G. Sfakiotaki
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - M. Perraki
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - S. Apostolaki
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - A. Kalykaki
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| | - V. Georgoulias
- Dept of Medcl Oncology, Univ Gen Hosp, Heraklion, Greece
| |
Collapse
|
19
|
Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis C, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. J BUON 2005; 10:47-52. [PMID: 17335131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
PURPOSE A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan (CPT-11), 5-fluorouracil/leucovorin (5-FU/LV) (AIO regimen) as salvage treatment in patients with metastatic colorectal cancer (MCC). PATIENTS AND METHODS Thirty-three patients relapsing after oxaliplatin-based first line chemotherapy were enrolled. There were 20 males and 13 females with median age of 69 years and WHO performance status (PS) of 0, 1, and 2 in 15, 16 and 2 patients, respectively. CPT-11 was administered on day 1 at 80 mg/m(2) in 60 min i.v. infusion, then LV (500 mg/m(2)) on day 1 as a 2h i.v. infusion, followed by 5-FU (2.600 mg/m(2)) as a 22h i.v. infusion. Treatment was repeated weekly for 6 consecutive weeks, in cycles of 7 weeks (one week rest). RESULTS All patients were evaluable for toxicity and response. Complete response (CR) was achieved in 2 (6%) patients and partial response (PR) in 4 (12%) (over-all response rate - ORR: 18%, 95% C.I.: 5.95-35.43); 13 patients (40%) had stable disease (SD) and 14 (42%) progressive disease (PD). After a median follow up period of 9 months the median duration of response was 5 months, the median time to tumor progression (TTP) 7.5 months and the median overall survival (OS) 14 months. Grade 3 and 4 neutropenia occured in 13 (39%) patients, febrile neutropeina in 3 (9%), and grade 4 thrombocytopenia in one (3%). Grade 3/4 diarrhea occured in 12 (36%) patients, grade 3/4 neurotoxicity in 3 (9%), and grade 3 asthenia in 4 (12%). There was no treatment-related death. CONCLUSION The combination of weekly CPT-11 and infusional 5-FU/LV is an active and relatively well-tolerated regimen as salvage treatment in MCC.
Collapse
Affiliation(s)
- J Souglakos
- Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Polyzos A, Mavroudis D, Boukovinas J, Tsiakopoulos E, Malamos N, Milaki G, Kouroussis C, Kotsakis A, Pallis A, Georgoulias V. A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.728] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Polyzos
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - D. Mavroudis
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - J. Boukovinas
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - E. Tsiakopoulos
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - N. Malamos
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - G. Milaki
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - C. Kouroussis
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - A. Kotsakis
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - A. Pallis
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| | - V. Georgoulias
- For the Breast Cancer Working Group, of the Hellenic Oncology Research Group (HORG), Greece
| |
Collapse
|
21
|
Androulakis N, Kouroussis C, Mavroudis D, Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A, Samonis G, Georgoulias V. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. Eur J Cancer 2002; 38:1992-7. [PMID: 12376203 DOI: 10.1016/s0959-8049(02)00168-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The aim of this study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLT) of a weekly administration of paclitaxel and pegylated liposomal doxorubicin (Caelyx; Schering Plough Pharmaceutical) in patients with advanced solid tumours. 19 pretreated patients with solid tumours received escalated doses of pegylated liposomal doxorubicin (6-12 mg/m(2)) as a 1-h intravenous (i.v.) infusion followed by a fixed dose of paclitaxel (80 mg/m(2)) weekly for 4 consecutive weeks in cycles of 6 weeks. DLT was defined as grade 4 neutropenia or thrombocytopenia, febrile neutropenia, grades 3 or 4 non-haematological toxicity or treatment delay due to unresolved toxicity during cycle 1. The MTD was reached at the dose of pegylated liposomal doxorubicin of 10 mg/m(2)/week and paclitaxel of 80 mg/m(2)/week. The DLTs were treatment delay due to grade 3 neutropenia and grade 3 diarrhoea. A total of 55 chemotherapy cycles were administered, and grades 3-4 neutropenia occurred in seven cycles (13%); the non-haematological toxicity was mild with grades 2/3 diarrhoea occurring in 4 (7%), grades 2-4 asthenia in 11 (20%) and grade 2 mucositis in 7 (13%) cycles. There was no case with more than a 10% LVEF decrease after a median of 3 (range 2-6) administered cycles/patients. One patient with breast cancer and 1 with ovarian cancer experienced a major partial response. The weekly administration of pegylated liposomal doxorubicin at the dose of 10 mg/m(2) in combination with paclitaxel at the dose of 80 mg/m(2) for 4 consecutive weeks, in cycles of 6 weeks which represent the recommended doses for further phase II studies, is a well tolerated regimen, which merits further evaluation in tumours known to be sensitive to taxanes and/or anthracyclines.
Collapse
Affiliation(s)
- N Androulakis
- Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Crete, Greece.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|